Datatrial to handle data collection to enhance the monitoring and management of patients with COVID-19

Datatrial are thrilled to announce they will be contributing to the fight against COVID-19 and in transforming the shape of clinical trial monitoring in the future.

2020 has proven to be a year that no one could have predicted. COVID-19 is a virus that the world will not forget in a hurry and 2020 is certainly a year that will go down in history. That is why Datatrial are thrilled to announce they will be contributing to the fight against COVID-19 and in transforming the shape of clinical trial monitoring in the future.

Datatrial’s data collection system, nowEDC, has been deployed to collect clinical data for the COSMIC-19 study (COntinuous Signs Monitoring in Covid-19 patients).  Working alongside Aptus Clinical Ltd, Datatrial will provide a compliant environment for data collection as well as the Nucleus platform to facilitate the integration and sharing of those data. The ultimate goal is to assist in the clinical management of patients with COVID-19.

‘ To see the systems that have been so studiously developed being used in the battle against the devastating consequences of COVID-19 is very rewarding.   Knowing that you may have contributed to a more positive outcome for just one patient is why we are so passionate about what we do.’

Julie Wright, Commercial Director, Datatrial

The trial, sponsored by The Christie NHS Foundation Trust in collaboration with Manchester University Foundation NHS Trust, allows hospitals to save hospital beds for those who are most critical. A wearable, wireless monitoring sensor will allow clinicians to identify and predict deteriorating patients faster and with less nurse to patient contact.  The study utilises advanced Artificial Intelligence (AI) capabilities provided by Zenzium.

‘We are delighted to be working with Datatrial on this important study, their open, collaborative approach has been a critical factor in Aptus being able to successfully support the operational delivery of the COSMIC-19 study. We look forward to continuing our partnership with Datatrial and making a difference to patients in future studies beyond COVID-19.’

Steve McConchie , CEO, Aptus Clinical